SYNTHESIS AND ANTI-TUMOR ACTIVITY OF NITROGEN SUBSTITUTED THALIDOMIDE ANALOGS

The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, nitrogen-substituted thalidomide analogs and di-substituted thalidomide analogs have been shown to inhibit angiogenesis. Importantly, these compounds can be administered orally.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/454
US CL : 514/323

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 514/323

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>US 6,228,879 B1 (GREEN et al) 08 May 2001 (08.05.2001), column 1, line 61 thru column 2, line 46; Figure 4.</td>
<td>10, 12-16</td>
</tr>
<tr>
<td>Y</td>
<td>wo 98/19649 A2 (THE CHILDREN'S MEDICAL CENTER CORPORATION) 14 May 1998 (14.05.1998), abstract; page 2, line 27 thru page 5, line 11; Figure 3; claims.</td>
<td>1-9, 13</td>
</tr>
</tbody>
</table>

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:
  *A* document defining the general state of the art which is not considered to be of particular relevance
  *E* earlier application or patent published on or after the international filing date
  *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  *O* document referring to an oral disclosure, use, exhibition or other means
  *P* document published prior to the international filing date but later than the priority date claimed

  *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  *E* document member of the same patent family

Date of the actual completion of the international search
24 January 2003 (24.01.2003)

Date of mailing of the international search report
11 FEB 2003

Form PCT/ISA/210 (second sheet) (July 1998)
Continuation of B. FIELDS SEARCHED Item 3:
STN ONLINE
search terms: aminothalidomide, thalidomide, angiogenesis, diabetic retinopathy, macular degeneration, corneal neovascularization